{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:30:29Z","timestamp":1762867829270,"version":"build-2065373602"},"reference-count":11,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.clml.2019.05.014","type":"journal-article","created":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T11:36:24Z","timestamp":1559129784000},"page":"e564-e567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Refractory \u03b1\/\u03b2-Hepatosplenic T-cell Lymphoma With Secondary CNS Dissemination and Severe Morbidity Related to Intrathecal Chemotherapy: A Case Report and Literature Review"],"prefix":"10.1016","volume":"19","author":[{"given":"Katharine L.","family":"Lewis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dejan","family":"Radeski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan Yoon","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.05.014_bib1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.05.014_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.humpath.2018.01.005","article-title":"Hepatosplenic T-cell lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors","volume":"74","author":"Yabe","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clml.2019.05.014_bib3","first-page":"137","article-title":"(18)F-FDG PET\/CT findings in hepatosplenic Gamma-Delta T-cell lymphoma: case reports and review of the literature","volume":"8","author":"Cho","year":"2018","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2019.05.014_bib4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00277-011-1257-5","article-title":"F-18 Fluorodeoxyglucose non-avid hepatosplenic T cell lymphoma: a diagnostic pitfall","volume":"91","author":"Ho","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2019.05.014_bib5","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.5858\/arpa.2014-0079-RS","article-title":"Hepatosplenic T-cell lymphoma: a clinicopathologic review with an emphasis on diagnostic differentiation from other T-cell\/natural killer\u2013cell neoplasms","volume":"139","author":"Shi","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.clml.2019.05.014_bib6","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood.V122.21.3032.3032","article-title":"Hepatosplenic T-cell lymphoma: clinicopathological features and treatment outcomes: report from the North American Peripheral T-Cell Lymphoma Consortium","volume":"122","author":"Wilson","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.05.014_bib7","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1182\/blood-2011-12-396150","article-title":"Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets","volume":"119","author":"Travert","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.05.014_bib8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00000478-200103000-00002","article-title":"Hepatosplenic \u03b1\u03b2 T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic \u03b3\u03b4 T-cell lymphomas","volume":"25","author":"Macon","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clml.2019.05.014_bib9","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bjh.13628","article-title":"Phase II study of HCVIDD\/MA in patients with newly diagnosed peripheral T-cell lymphoma","volume":"171","author":"Chihara","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.05.014_bib10","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2003-05-1675","article-title":"Hepatosplenic \u03b3\u03b4 T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients","volume":"102","author":"Belhadj","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.05.014_bib11","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11060-015-1727-z","article-title":"Myelopathy following intrathecal chemotherapy in adults: a single institution experience","volume":"122","author":"Cachia","year":"2015","journal-title":"J\u00a0Neurooncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019302794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019302794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:33:22Z","timestamp":1761870802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019302794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":11,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S2152265019302794"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.05.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Refractory \u03b1\/\u03b2-Hepatosplenic T-cell Lymphoma With Secondary CNS Dissemination and Severe Morbidity Related to Intrathecal Chemotherapy: A Case Report and Literature Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}